Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors.
Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors.
复制标题
血清素作为颅面形态发生的调节剂：暴露于血清素摄取抑制剂后出现部位特异性畸形。
DOI：
10.1002/tera.1420460407
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Lauder,JM
中科院分区：
文献类型：
--
作者：
Shuey,DL;Sadler,TW;Lauder,JM
During craniofacial development in the mouse embryo (days 9–12 of gestation; plug day= day 1), transient expression of serotonin (5-HT) uptake in epithelial structures of this region correlates with critical morphogenetic events (Lauder et al.,'88; Shuey,'91; Shuey et al.,'89,'92). The purpose of the present investigation was to assess the possible functional significance of these uptake sites by examination of patterns of dysmorphology following exposure of embryos to selective 5-HT uptake inhibitors. Exposure of mouse embryos in whole embryo culture to sertraline, at a concentration (10 μM) which produced no evidence of general embryotoxicity, caused craniofacial malformations consistent with direct action at 5-HT uptake sites. Two other 5-HT uptake inhibitors, fluoxetine and amitriptyline, produced similar defects. The critical period of sertraline exposure occurred on days 10–11. The observed craniofacial defects were associated with decreased proliferation and extensive cell death in mesenchyme located 5–6 cell layers deep from the overlying epithelium. In contrast, the subepithelial mesenchymal layers showed normal or elevated levels of proliferation. From these results it appears that inhibition of 5-HT uptake into craniofacial epithelia may produce developmental defects by interference with serotonergic regulation of epithelial–mesenchymal interactions important for normal craniofacial morphogenesis.© 1992 Wiley-Liss, Inc.
